PTPRH

Across TCGA pan-cancer cohorts, PTPRH Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated PTPRH data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PTPRH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRH expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

THYM, UCEC, and LUAD are the cancer types where PTPRH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	II,III,IV	0.893	0.429	.008	24	view →
LUAD	OS	Median	II,III,IV	0.329	0.694	<.001	24	view →
PAAD	OS	Median	All	0.117	0.613	<.001	21	view →
OV	OS	Median	III,IV	0.235	0.685	.003	18	view →
LIHC	OS	Median	II,III,IV	0.210	0.722	<.001	18	view →
BLCA	OS	Median	II,III,IV	1.000	0.595	.016	8	view →
PRAD	OS	Median	All	0.880	0.990	<.001	8	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.018	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
LUSC	OS	Median	All	0.505	0.818	.006	5	view →
LGG	OS	Median	All	0.535	0.911	.007	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

PTPRH–THYM (OS)

Open the THYM breakdown →